Aceragen, Inc.

NasdaqCM:ACGN 주식 보고서

시가총액: US$3.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aceragen 대차 대조표 상태

재무 상태 기준 확인 2/6

Aceragen has a total shareholder equity of $57.3M and total debt of $733.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are $78.5M and $21.1M respectively.

주요 정보

1.3%

부채 비율

US$733.00k

부채

이자 보상 비율n/a
현금US$2.12m
주식US$57.35m
총 부채US$21.14m
총 자산US$78.49m

최근 재무 상태 업데이트

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31
When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27
Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27
Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Nov 25
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Idera Pharma names new operations chief

Nov 17

Idera Pharmaceuticals EPS misses by $0.37

Oct 29

재무 상태 분석

단기부채: ACGN's short term assets ($5.6M) do not cover its short term liabilities ($17.9M).

장기 부채: ACGN's short term assets ($5.6M) exceed its long term liabilities ($3.3M).


부채 대 자본 내역 및 분석

부채 수준: ACGN has more cash than its total debt.

부채 감소: ACGN's debt to equity ratio has increased from 0.1% to 1.3% over the past 5 years.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: ACGN has less than a year of cash runway based on its current free cash flow.

예측 현금 활주로: ACGN has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.3% each year.


건강한 기업 발견하기